Hormone Optimization with Peptide Therapy

Educational content only. The following article is based on published scientific research and is provided for informational purposes. It does not constitute medical advice, diagnosis, or a treatment recommendation. Individual responses to any therapy vary. All peptide protocols at Irvine Health are available only after a licensed physician video consultation and a written prescription.

Hormone optimization is a broad clinical area addressing the natural decline in key hormones that occurs with aging — including growth hormone, testosterone (in men), estrogen and progesterone (in women), DHEA, thyroid hormones, and insulin-like growth factor-1 (IGF-1). Peptides play a role in hormone optimization in two ways: some peptides directly stimulate endocrine glands to produce hormones (secretagogues), while others modulate the signaling environment in which hormones act. This article focuses on the peptide-based aspects of hormone support.

Growth Hormone Secretagogues in Hormone Optimization

The somatopause — age-related decline in GH and IGF-1 — begins in the third decade of life and continues at approximately 14% per decade. GH decline is associated with changes in body composition (increased visceral fat, decreased lean mass), reduced bone density, decreased energy, and impaired recovery. GH secretagogue peptides — including CJC-1295, ipamorelin, GHRP-2, and sermorelin — aim to restore more youthful patterns of pulsatile GH release by stimulating the pituitary rather than administering exogenous GH directly.

Sermorelin Clinical Data — Walker RF, Drugs Aging (2006)

Sermorelin is a 29-amino-acid GHRH analogue that has the longest history of clinical use among GH secretagogues, having received FDA approval for the treatment of idiopathic growth hormone deficiency in children (approval subsequently withdrawn for commercial reasons, not safety). Adult clinical studies with sermorelin demonstrated increases in IGF-1, lean body mass, and bone density in GH-deficient adults — providing the clinical precedent for secretagogue-based GH support.

Kisspeptin and Reproductive Hormones

Kisspeptin in Hypogonadotropic Hypogonadism — Dhillo et al., J Clin Endocrinol Metab (2005)

Kisspeptin is a neuropeptide encoded by the KISS1 gene that acts on GPR54 receptors in the hypothalamus to stimulate GnRH (gonadotropin-releasing hormone) secretion. Research has characterized kisspeptin as a master regulator of the reproductive axis. Clinical studies have used kisspeptin infusions to stimulate LH and FSH secretion in patients with hypogonadotropic hypogonadism, demonstrating that the GnRH pulse generator can be activated via this peptide pathway.

PT-141 (Bremelanotide) and Sexual Health

Female Hypoactive Sexual Desire — FDA Approval 2019

Bremelanotide (PT-141) is a melanocortin receptor agonist developed from Melanotan II that acts centrally in the hypothalamus to modulate sexual motivation pathways. It received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women — making it one of the few peptide therapies to achieve FDA approval in the hormonal/sexual health space. Unlike phosphodiesterase inhibitors, its mechanism operates upstream through central nervous system melanocortin pathways rather than peripheral vascular effects.

Thyroid and Adrenal Considerations

Complete hormone optimization evaluation typically encompasses thyroid function (TSH, free T3, free T4), adrenal function (DHEA-S, cortisol rhythm), sex hormones (testosterone, estradiol, progesterone, LH, FSH), and metabolic markers (fasting insulin, glucose, IGF-1). Peptide therapies are one component of a broader hormone evaluation and optimization strategy that a licensed provider assembles based on comprehensive lab review and clinical history.

References

Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-8.
Dhillo WS, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005;90(12):6609-15.
FDA. Highlights of Prescribing Information: Vyleesi (bremelanotide) injection. 2019.
Veldhuis JD. Aging and hormones of the hypothalamo-pituitary axis: gonadotropic axis in men and somatotropic axes in men and women. Ageing Res Rev. 2008;7(3):189-208.